心臟移植市場：依手術方法、適應症、移植心臟保存方法、病患年齡層和最終用戶分類－2026-2032年全球市場預測

2025 年心臟移植市場價值為 144.1 億美元，預計到 2026 年將成長至 158.6 億美元，年複合成長率為 10.41%，到 2032 年將達到 288.5 億美元。

主要市場統計數據
基準年 2025	144.1億美元
預計年份：2026年	158.6億美元
預測年份 2032	288.5億美元
複合年成長率 (%)	10.41%

重點概述正在重塑心臟移植計畫和相關人員決策的現代臨床、供應鏈和策略重點。

本執行摘要在於心臟移植的現狀，整合了臨床進展、供應鏈趨勢、監管影響和營運重點，這些因素正在塑造專案層面和產業層面的策略。概述著重介紹了重新定義圍手術全期護理、器官保存、供受者匹配和跨境物流的關鍵轉折點，並強調了這些轉折點對醫院管理者、移植中心、醫療設備開發商和醫療保健系統採購人員的重要意義。

器官灌注技術、外科手術改進和護理模式的重新設計等方面的技術創新，是如何為整個心臟移植服務體系帶來結構性變化的？

心臟移植領域正經歷著變革性的轉變，這主要得益於技術創新、臨床方案的不斷改進以及器官保存和分配方式的轉變。器官灌注技術的進步延長了器官的存活期，並擴大了捐贈者範圍。因此，手術時機、受體選擇框架和物流模式都在改變。同時，手術技術和手術全期管理的改進正在提高移植器官的功能和早期存活率，為各中心重新評估患者診療路徑和容量規劃提供了機會。

本研究評估了美國 2025 年收費調整將如何影響心臟移植醫學中的器官獲取經濟、供應鏈韌性和技術採用決策。

美國2025年實施的政策變化，特別是關稅調整，將使心臟移植供應鏈更加複雜，影響醫療設備、儲存系統和跨境物流。對某些醫療設備和組件徵收關稅可能會增加移植手術專用設備的總成本，從而影響醫院和移植中心的採購預算。隨著採購成本的上升，專案負責人面臨艱難的權衡：是繼續使用現有供應商，還是投資於具有潛在臨床效益但初期實施成本可能較高的新興技術。

臨床和營運方面的實際情況決定了採購和計畫實施的選擇，重點在於治療、適應症、保存方法、年齡層和最終用戶等各個方面。

細分市場層面的趨勢揭示了明確的臨床和營運需求，這些需求應納入專案規劃和供應商選擇。異位移植和原位移植在手術操作上的差異仍然是外科決策的關鍵，其中原位移植可進一步細分為雙心房入路和雙側下腔靜脈入路，這會影響圍手術全期管理、併發症趨勢和資源利用。這些手術操作類別的差異指南人員配置模式、訓練需求和器械適用性評估。

臨床實施的複雜性、監管挑戰以及美洲、歐洲、中東和非洲以及亞太地區供應鏈策略的區域差異，正在影響實施路徑。

區域趨勢塑造了臨床實踐模式、法規環境和供應鏈結構，從而為不同地區的相關人員創造了不同的策略重點。在美洲，成熟的移植網路和整合資料系統為先進的供受者匹配和保存技術創新的快速應用提供了支持，使各機構受益匪淺。然而，他們也必須應對報銷方案的區域差異和州級監管差異，這些差異會影響資本規劃和採購週期。

競爭格局的特點是技術創新公司、成熟的醫療設備製造商以及優先考慮臨床檢驗、整合和靈活商業模式的服務合作夥伴。

支持心臟移植醫學的企業格局呈現出多元化的特點，既有專注於技術創新的公司，也有成熟的醫療設備製造商，以及為物流和保存提供支援的服務供應商。專注於機械灌注和器官保存系統的創新公司，正透過平台開發、數據驅動的監測以及與運輸和物流的整合，推動傳統冷凍保存模式的變革。同時，大型醫療設備製造商正利用其分銷規模、監管經驗以及與臨床機構的良好關係，加速市場滲透並推廣新技術培訓計畫。

為確保該計劃的持續韌性和成功，醫院經營團隊、移植中心主任和供應商正在採取切實可行的策略措施，以協調採購、臨床實踐和夥伴關係。

產業領導者和專案主管應採取果斷措施，使臨床目標與採購和營運策略保持一致。優先投資於那些能夠提高器官存活率和運作柔軟性的保存平台，並在實施這些平台的同時，制定完善的培訓計劃和跨學科規範，以確保其一致使用並發揮最佳效果。此外，還應採用能夠評估總擁有成本 (TCO)、供應冗餘和服務等級協定 (SLA) 的採購框架，以保護專案免受因供應中斷和關稅波動造成的成本影響。

透過嚴格整合臨床文獻、相關人員訪談、方案分析和操作檢驗等證據，得出可操作的項目層面見解。

本執行摘要依據的研究整合了同行評審的臨床文獻、監管指南、手術技術分析以及來自移植臨床醫生、供應鏈負責人和技術開發人員的原始定性數據。資料收集包括與多學科相關人員進行結構化訪談、檢驗臨床方案和醫療設備使用說明書，以及審查與採購和價格波動影響相關的政策文件。分析方法結合了主題定性整合和手術及保守治療方法操作要求的比較評估。

整合臨床、營運和策略要求，以確定能夠在維持韌性和患者療效的同時，從創新中受益的移植項目。

總之，心臟移植領域正處於一個轉折點，臨床創新、保存模式的轉變以及不斷演變的供應鏈動態在此交匯，重新定義了專案策略。灌注技術的進步以及手術和手術全期護理的改進，為擴大捐贈者來源和改善治療效果創造了機會。同時，政策變化和取得方面的挑戰要求採用更完善的供應鏈和合約管理方法。成功的專案將整合臨床和營運規劃，採用循證技術並提供相應的培訓和支持，同時建立採購系統以應對成本波動和供應風險。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 市場進入策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以手術方式分類的心臟移植市場

• 異位移植
• 移植到同一地點
  • 雙心房法
  • 雙側下腔靜脈法

第9章：心臟移植市場：依適應症分類

• 先天性心臟疾病
• 擴大性心肌病
• 末期心臟衰竭
• 缺血性心肌病變

第10章：以移植保存方法分類的心臟移植市場

• 機械灌注
  • 低溫灌注
  • 正常體溫灌注
• 室溫下冷藏保存。

第11章：依病患年齡層別分類的心臟移植市場

• 成人版
• 老年人
• 兒童

第12章 心臟移植市場：依最終用戶分類

• 醫院
• 移植中心

第13章 心臟移植市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 心臟移植市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 心臟移植市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國心臟移植市場

第17章：中國心臟移植市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Abbott Laboratories
• Abiomed, Inc.
• Berlin Heart GmbH
• BiVACOR, Inc.
• Calon Cardio-Technology Ltd.
• CARMAT SA
• CH Biomedical, Inc.
• Cleveland Heart, Inc.
• CorWave SA
• Evaheart, Inc.
• FineHeart SA
• Jarvik Heart, Inc.
• Leviticus Cardio Ltd.
• LivaNova plc
• Medtronic plc
• NuPulseCV, Inc.
• ReliantHeart, Inc.
• Sun Medical Technology Research Corporation
• SynCardia Systems LLC
• Syntach AB
• Thoratec Corporation
• Windmill Cardiovascular Systems, Inc.

The Heart Transplant Market was valued at USD 14.41 billion in 2025 and is projected to grow to USD 15.86 billion in 2026, with a CAGR of 10.41%, reaching USD 28.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 14.41 billion
Estimated Year [2026]	USD 15.86 billion
Forecast Year [2032]	USD 28.85 billion
CAGR (%)	10.41%

A focused orientation to contemporary clinical, supply chain, and strategic priorities that are reshaping heart transplant programs and stakeholder decision-making

This executive summary offers a focused orientation to the contemporary heart transplant landscape, synthesizing clinical advances, supply chain dynamics, regulatory influences, and operational priorities that shape program-level and industry-level strategy. The overview highlights critical inflection points that are redefining perioperative practice, organ preservation, donor-recipient matching, and cross-border logistics while clarifying the implications for hospital administrators, transplant centers, medical device developers, and health system purchasers.

Through integrated analysis of clinical protocols and industry developments, this summary frames the most consequential trends and tensions facing the ecosystem. It seeks to align clinical quality imperatives with procurement realities and technological opportunities. By emphasizing both immediate operational levers and medium-term strategic shifts, the content provides a pragmatic roadmap for stakeholders aiming to optimize outcomes, control costs, and accelerate adoption of high-value innovations. The intent is to enable informed conversations among clinicians, administrators, and supply chain leaders about priorities and investment decisions that will materially influence program resilience and patient outcomes moving forward.

How technological innovation in organ perfusion, surgical refinement, and care model redesign are catalyzing structural change across heart transplant delivery systems

The heart transplant field is undergoing transformative shifts driven by technological innovation, evolving clinical protocols, and changes in how organs are preserved and allocated. Advances in organ perfusion technologies are extending viable preservation times and broadening donor criteria, which in turn is altering surgical timing, recipient selection frameworks, and logistics models. Concurrently, refinement of surgical techniques and perioperative management is improving graft function and early survival, creating opportunities for centers to reconsider patient pathways and capacity planning.

Other forces of change include the integration of data-driven donor-recipient matching, improvements in immunosuppression strategies, and growing emphasis on multidisciplinary post-transplant care models that balance survival with long-term quality of life. The confluence of these developments is prompting hospitals and transplant centers to reassess infrastructure investments, staff competencies, and partnerships with device and preservation technology suppliers. As these shifts unfold, program leaders are increasingly required to adopt flexible procurement strategies and to collaborate across clinical, operational, and supply chain domains to capture clinical benefits while managing complexity and cost.

Assessing how 2025 tariff adjustments in the United States are altering procurement economics, supply chain resilience, and technology adoption decisions in heart transplant care

Policy changes enacted in 2025 by the United States, specifically tariff adjustments, have introduced a layer of complexity to the heart transplant supply chain that affects devices, preservation systems, and cross-border logistics. Tariffs on certain medical devices and components can increase landed costs for specialized equipment used in transplants, impacting procurement budgets at hospitals and transplant centers. When procurement costs rise, program directors face difficult trade-offs between retaining established suppliers and investing in emergent technologies that promise clinical advantages but may have higher initial acquisition costs.

Tariff-driven cost pressures also influence global distribution patterns for preservation media, single-use components, and perfusion platforms. Logistic adaptations have emerged as providers seek alternative sourcing strategies, localized inventories, and contractual protections to mitigate supply disruption risks. Additionally, tariffs may have indirect clinical implications by constraining the availability of particular consumables or limiting rapid deployment of new devices that require internationally manufactured components. To navigate this environment, stakeholders are engaging more proactively with suppliers on pricing, investing in redundancy for critical supplies, and reassessing total cost of ownership rather than upfront price alone, thereby preserving program resilience and clinical continuity.

Segment-focused clinical and operational realities across procedure, indication, preservation, age group, and end user that determine procurement and program implementation choices

Segment-level dynamics reveal distinct clinical and operational imperatives that must be integrated into program planning and vendor selection. Procedure distinctions between heterotopic and orthotopic transplant remain foundational to surgical decision-making, with orthotopic approaches subdivided into biatrial and bicaval techniques that influence perioperative management, complication profiles, and resource utilization. Such procedural categorical differences guide staffing models, training needs, and device compatibility assessments.

Indication-based segmentation highlights varied patient cohorts such as congenital heart disease, dilated cardiomyopathy, end-stage heart failure, and ischemic cardiomyopathy, each of which carries unique pre-transplant optimization requirements and post-transplant care pathways. These clinical indications also shape allocation priorities and anticipated comorbidity burdens, informing length-of-stay projections and long-term follow-up strategies. Graft preservation choices between machine perfusion and static cold storage, and within machine perfusion between hypothermic and normothermic modalities, affect transport logistics, perfusion staffing, and decisions around investment in perfusion platforms. Patient age group distinctions across adult, geriatric, and pediatric populations have meaningful implications for graft selection criteria, immunosuppression protocols, and rehabilitation planning. Lastly, end users such as hospitals and transplant centers vary in scale, case mix, and integration with broader health systems, which drives differences in purchasing structures, preferred contracting approaches, and readiness to adopt new preservation and monitoring technologies. Understanding how these segments interact is essential for aligning clinical protocols with procurement strategy and for tailoring implementation plans that deliver consistent outcomes across program types.

Regional differentiation in clinical adoption, regulatory complexity, and supply chain strategy across the Americas, Europe Middle East & Africa, and Asia-Pacific that shapes implementation pathways

Regional dynamics shape clinical practice patterns, regulatory environments, and supply chain architectures, creating distinct strategic priorities for stakeholders operating in different geographies. In the Americas, centers benefit from mature transplant networks and integrated data systems that support advanced donor-recipient matching and rapid adoption of preservation innovations, yet they must also contend with differential reimbursement landscapes and state-level regulatory variability that influence capital planning and procurement cycles.

In Europe, the Middle East & Africa, heterogeneity in regulatory frameworks and infrastructure maturity drives a two-speed market where leading transplant centers adopt cutting-edge technologies while many institutions focus on foundational capacity building and supply chain stabilization. This regional mix affects partnership models and distribution strategies. In the Asia-Pacific region, expanding clinical capacity, evolving regulatory pathways, and active investment in medical technology infrastructure are accelerating uptake of novel preservation and monitoring solutions, but logistical complexity across vast geographies and variances in reimbursement can influence market entry strategies and localization efforts. Across all regions, cross-border collaboration, harmonization of clinical protocols, and strategic alliances with local distributors remain decisive factors in successful technology deployment and program scaling.

Competitive dynamics characterized by technology innovators, established device manufacturers, and service alliances that prioritize clinical validation, integration, and flexible commercial models

The corporate landscape supporting heart transplant care is marked by a mix of specialized technology innovators, established medical device manufacturers, and service providers that support logistics and preservation. Innovators focused on machine perfusion and organ preservation systems are driving a shift away from traditional cold storage models through platform development, data-enabled monitoring, and integration with transport logistics. At the same time, larger device manufacturers are leveraging distribution scale, regulatory experience, and clinical relationships to accelerate market penetration and facilitate training programs for new technologies.

Strategic partnerships between technology developers, transplant centers, and logistics providers are becoming more common, combining clinical validation pathways with operational solutions to manage organ transport and device uptime. Companies that emphasize robust clinical evidence, user-centered design, and lifecycle service support tend to achieve greater acceptance among program directors. Additionally, firms that offer flexible commercial models-such as outcome-oriented contracts, managed service arrangements, or bundled procurement options-are gaining traction as customers seek to align clinical benefits with predictable budgetary outcomes. Competitive differentiation increasingly depends on demonstrating clinical value, enabling seamless integration into clinical workflows, and supporting post-deployment training and data analytics.

Actionable strategic measures for hospital executives, transplant center leaders, and vendors to align procurement, clinical practice, and partnerships for sustained program resilience and outcomes

Industry leaders and program directors should take decisive steps to align clinical goals with procurement and operational strategies. Prioritize investments in preservation platforms that have demonstrated improvements in organ viability and operational flexibility, and pair those acquisitions with robust training programs and cross-disciplinary protocols to ensure consistent use and benefit realization. Simultaneously, adopt procurement frameworks that evaluate total cost of ownership, supply redundancy, and service-level agreements to protect programs against supply interruptions and tariff-driven cost volatility.

Cultivate strategic partnerships with logistics and technology providers to co-design transport and preservation workflows that reduce ischemic time and improve predictability. Invest in data capture and analytics to measure clinical outcomes, identify process bottlenecks, and support evidence-based contracting. Finally, engage with policymakers and payers to communicate the clinical and economic value of advanced preservation technologies, seeking reimbursement models or innovative contracting approaches that align incentives for early adoption and long-term patient benefit. These coordinated actions will position programs to capture clinical gains while maintaining fiscal discipline and operational resilience.

A rigorous evidence synthesis combining clinical literature, stakeholder interviews, protocol analysis, and operational validation to produce actionable program-level insights

The research underpinning this executive summary synthesizes peer-reviewed clinical literature, regulatory guidance, operative technique analyses, and primary qualitative inputs from transplant clinicians, supply chain leaders, and technology developers. Data collection included structured interviews with multidisciplinary stakeholders, examination of clinical protocols and device instructions for use, and review of policy documents pertinent to procurement and tariff impacts. Analytical methods combined thematic qualitative synthesis with comparative assessment of operational requirements across procedural and preservation modalities.

To ensure relevance for practitioners and decision-makers, the methodology prioritized triangulation across clinical evidence, supplier capabilities, and real-world operational experience. Insights were validated through iterative consultations with transplant surgeons, perfusionists, and program administrators to align findings with frontline practice. The research explicitly focused on system-level implications and technological adoption considerations rather than on granular financial estimates, enabling practical recommendations suited to diverse institutional contexts and readiness levels.

Synthesis of clinical, operational, and strategic imperatives that will determine which transplant programs capture the benefits of innovation while preserving resilience and patient outcomes

In conclusion, the heart transplant domain is at an inflection point where clinical innovation, shifting preservation paradigms, and evolving supply chain dynamics are converging to redefine program strategy. Advances in perfusion technologies and refinements in surgical and perioperative care are creating opportunities to expand donor pools and improve outcomes, while policy changes and procurement challenges necessitate more sophisticated supply chain and contracting approaches. Successful programs will be those that integrate clinical and operational planning, adopt evidence-backed technologies with appropriate training and support, and structure procurement to manage cost volatility and supply risk.

Looking ahead, the most resilient transplant programs will be those that combine clinical excellence with strategic procurement, data-driven performance management, and collaborative partnerships across the clinical and commercial ecosystem. By aligning investments with validated clinical benefits and operational readiness, stakeholders can improve patient outcomes, enhance program sustainability, and accelerate the adoption of innovations that meaningfully advance transplant care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Transplant Market, by Procedure

• 8.1. Heterotopic Transplant
• 8.2. Orthotopic Transplant
  • 8.2.1. Biatrial Technique
  • 8.2.2. Bicaval Technique

9. Heart Transplant Market, by Indication

• 9.1. Congenital Heart Disease
• 9.2. Dilated Cardiomyopathy
• 9.3. End Stage Heart Failure
• 9.4. Ischemic Cardiomyopathy

10. Heart Transplant Market, by Graft Preservation

• 10.1. Machine Perfusion
  • 10.1.1. Hypothermic Perfusion
  • 10.1.2. Normothermic Perfusion
• 10.2. Static Cold Storage

11. Heart Transplant Market, by Patient Age Group

• 11.1. Adult
• 11.2. Geriatric
• 11.3. Pediatric

12. Heart Transplant Market, by End User

• 12.1. Hospitals
• 12.2. Transplant Centers

13. Heart Transplant Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Heart Transplant Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Heart Transplant Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Heart Transplant Market

17. China Heart Transplant Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Abbott Laboratories
• 18.6. Abiomed, Inc.
• 18.7. Berlin Heart GmbH
• 18.8. BiVACOR, Inc.
• 18.9. Calon Cardio-Technology Ltd.
• 18.10. CARMAT SA
• 18.11. CH Biomedical, Inc.
• 18.12. Cleveland Heart, Inc.
• 18.13. CorWave SA
• 18.14. Evaheart, Inc.
• 18.15. FineHeart SA
• 18.16. Jarvik Heart, Inc.
• 18.17. Leviticus Cardio Ltd.
• 18.18. LivaNova plc
• 18.19. Medtronic plc
• 18.20. NuPulseCV, Inc.
• 18.21. ReliantHeart, Inc.
• 18.22. Sun Medical Technology Research Corporation
• 18.23. SynCardia Systems LLC
• 18.24. Syntach AB
• 18.25. Thoratec Corporation
• 18.26. Windmill Cardiovascular Systems, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HEART TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL HEART TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HEART TRANSPLANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL HEART TRANSPLANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HETEROTOPIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HETEROTOPIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HETEROTOPIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BIATRIAL TECHNIQUE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BIATRIAL TECHNIQUE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BIATRIAL TECHNIQUE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BICAVAL TECHNIQUE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BICAVAL TECHNIQUE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL HEART TRANSPLANT MARKET SIZE, BY BICAVAL TECHNIQUE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL HEART TRANSPLANT MARKET SIZE, BY CONGENITAL HEART DISEASE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL HEART TRANSPLANT MARKET SIZE, BY CONGENITAL HEART DISEASE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL HEART TRANSPLANT MARKET SIZE, BY CONGENITAL HEART DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL HEART TRANSPLANT MARKET SIZE, BY DILATED CARDIOMYOPATHY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL HEART TRANSPLANT MARKET SIZE, BY DILATED CARDIOMYOPATHY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL HEART TRANSPLANT MARKET SIZE, BY DILATED CARDIOMYOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL HEART TRANSPLANT MARKET SIZE, BY END STAGE HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL HEART TRANSPLANT MARKET SIZE, BY END STAGE HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL HEART TRANSPLANT MARKET SIZE, BY END STAGE HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ISCHEMIC CARDIOMYOPATHY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ISCHEMIC CARDIOMYOPATHY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ISCHEMIC CARDIOMYOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HYPOTHERMIC PERFUSION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HYPOTHERMIC PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HYPOTHERMIC PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL HEART TRANSPLANT MARKET SIZE, BY NORMOTHERMIC PERFUSION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL HEART TRANSPLANT MARKET SIZE, BY NORMOTHERMIC PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL HEART TRANSPLANT MARKET SIZE, BY NORMOTHERMIC PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL HEART TRANSPLANT MARKET SIZE, BY STATIC COLD STORAGE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL HEART TRANSPLANT MARKET SIZE, BY STATIC COLD STORAGE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL HEART TRANSPLANT MARKET SIZE, BY STATIC COLD STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL HEART TRANSPLANT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL HEART TRANSPLANT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL HEART TRANSPLANT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL HEART TRANSPLANT MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL HEART TRANSPLANT MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL HEART TRANSPLANT MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL HEART TRANSPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. AMERICAS HEART TRANSPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 62. AMERICAS HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 68. AMERICAS HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 69. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 74. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 75. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 76. NORTH AMERICA HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 82. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 83. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 84. LATIN AMERICA HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE, MIDDLE EAST & AFRICA HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 96. EUROPE HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 98. EUROPE HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 99. EUROPE HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 100. EUROPE HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 101. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 103. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 104. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 105. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 106. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 107. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 108. MIDDLE EAST HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 109. AFRICA HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 110. AFRICA HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 111. AFRICA HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 112. AFRICA HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 113. AFRICA HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 114. AFRICA HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 115. AFRICA HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 116. AFRICA HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 117. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 119. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 120. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 121. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 122. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 123. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 124. ASIA-PACIFIC HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL HEART TRANSPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 126. ASEAN HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 127. ASEAN HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 128. ASEAN HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 129. ASEAN HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 130. ASEAN HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 131. ASEAN HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 132. ASEAN HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 133. ASEAN HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 134. GCC HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 135. GCC HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 136. GCC HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 137. GCC HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 138. GCC HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 139. GCC HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 140. GCC HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 141. GCC HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 142. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 143. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 144. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 145. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 146. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 147. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 148. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 149. EUROPEAN UNION HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 150. BRICS HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 151. BRICS HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 152. BRICS HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 153. BRICS HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 154. BRICS HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 155. BRICS HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 156. BRICS HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 157. BRICS HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 158. G7 HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 159. G7 HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 160. G7 HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 161. G7 HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 162. G7 HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 163. G7 HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 164. G7 HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 165. G7 HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 166. NATO HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 167. NATO HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 168. NATO HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 169. NATO HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 170. NATO HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 171. NATO HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 172. NATO HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 173. NATO HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 174. GLOBAL HEART TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 175. UNITED STATES HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 176. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 177. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 178. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 179. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 180. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 181. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 182. UNITED STATES HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 183. CHINA HEART TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 184. CHINA HEART TRANSPLANT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
• TABLE 185. CHINA HEART TRANSPLANT MARKET SIZE, BY ORTHOTOPIC TRANSPLANT, 2018-2032 (USD MILLION)
• TABLE 186. CHINA HEART TRANSPLANT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 187. CHINA HEART TRANSPLANT MARKET SIZE, BY GRAFT PRESERVATION, 2018-2032 (USD MILLION)
• TABLE 188. CHINA HEART TRANSPLANT MARKET SIZE, BY MACHINE PERFUSION, 2018-2032 (USD MILLION)
• TABLE 189. CHINA HEART TRANSPLANT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 190. CHINA HEART TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)